These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 17352934

  • 1. Depletion of Complexin II does not affect disease progression in a mouse model of Huntington's disease (HD); support for role for complexin II in behavioural pathology in a mouse model of HD.
    Glynn D, Reim K, Brose N, Morton AJ.
    Brain Res Bull; 2007 Apr 30; 72(2-3):108-20. PubMed ID: 17352934
    [Abstract] [Full Text] [Related]

  • 2. A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse.
    Gibson HE, Reim K, Brose N, Morton AJ, Jones S.
    Eur J Neurosci; 2005 Oct 30; 22(7):1701-12. PubMed ID: 16197510
    [Abstract] [Full Text] [Related]

  • 3. Complexin II is essential for normal neurological function in mice.
    Glynn D, Bortnick RA, Morton AJ.
    Hum Mol Genet; 2003 Oct 01; 12(19):2431-48. PubMed ID: 12915444
    [Abstract] [Full Text] [Related]

  • 4. Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation.
    Freeman W, Morton AJ.
    Brain Res Bull; 2004 Mar 01; 63(1):45-55. PubMed ID: 15121238
    [Abstract] [Full Text] [Related]

  • 5. Profound ataxia in complexin I knockout mice masks a complex phenotype that includes exploratory and habituation deficits.
    Glynn D, Drew CJ, Reim K, Brose N, Morton AJ.
    Hum Mol Genet; 2005 Aug 15; 14(16):2369-85. PubMed ID: 16000319
    [Abstract] [Full Text] [Related]

  • 6. Atrophy and degeneration in sciatic nerve of presymptomatic mice carrying the Huntington's disease mutation.
    Wade A, Jacobs P, Morton AJ.
    Brain Res; 2008 Jan 10; 1188():61-8. PubMed ID: 18062944
    [Abstract] [Full Text] [Related]

  • 7. Complexin 1 knockout mice exhibit marked deficits in social behaviours but appear to be cognitively normal.
    Drew CJ, Kyd RJ, Morton AJ.
    Hum Mol Genet; 2007 Oct 01; 16(19):2288-305. PubMed ID: 17652102
    [Abstract] [Full Text] [Related]

  • 8. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms.
    Bailey CD, Johnson GV.
    J Neurochem; 2005 Jan 01; 92(1):83-92. PubMed ID: 15606898
    [Abstract] [Full Text] [Related]

  • 9. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.
    Zourlidou A, Gidalevitz T, Kristiansen M, Landles C, Woodman B, Wells DJ, Latchman DS, de Belleroche J, Tabrizi SJ, Morimoto RI, Bates GP.
    Hum Mol Genet; 2007 May 01; 16(9):1078-90. PubMed ID: 17360721
    [Abstract] [Full Text] [Related]

  • 10. Increased thirst and drinking in Huntington's disease and the R6/2 mouse.
    Wood NI, Goodman AO, van der Burg JM, Gazeau V, Brundin P, Björkqvist M, Petersén A, Tabrizi SJ, Barker RA, Morton AJ.
    Brain Res Bull; 2008 May 15; 76(1-2):70-9. PubMed ID: 18395613
    [Abstract] [Full Text] [Related]

  • 11. Clorgyline-mediated reversal of neurological deficits in a Complexin 2 knockout mouse.
    Glynn D, Gibson HE, Harte MK, Reim K, Jones S, Reynolds GP, Morton AJ.
    Hum Mol Genet; 2010 Sep 01; 19(17):3402-12. PubMed ID: 20584925
    [Abstract] [Full Text] [Related]

  • 12. Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation.
    Ribchester RR, Thomson D, Wood NI, Hinks T, Gillingwater TH, Wishart TM, Court FA, Morton AJ.
    Eur J Neurosci; 2004 Dec 01; 20(11):3092-114. PubMed ID: 15579164
    [Abstract] [Full Text] [Related]

  • 13. The protective effects of cystamine in the R6/2 Huntington's disease mouse involve mechanisms other than the inhibition of tissue transglutaminase.
    Bailey CD, Johnson GV.
    Neurobiol Aging; 2006 Jun 01; 27(6):871-9. PubMed ID: 15896882
    [Abstract] [Full Text] [Related]

  • 14. "Brain training" improves cognitive performance and survival in a transgenic mouse model of Huntington's disease.
    Wood NI, Glynn D, Morton AJ.
    Neurobiol Dis; 2011 Jun 01; 42(3):427-37. PubMed ID: 21324361
    [Abstract] [Full Text] [Related]

  • 15. Behavioural state differentially engages septohippocampal cholinergic and GABAergic neurons in R6/1 Huntington's disease mice.
    Ransome MI, Hannan AJ.
    Neurobiol Learn Mem; 2012 Feb 01; 97(2):261-70. PubMed ID: 22261461
    [Abstract] [Full Text] [Related]

  • 16. Vulnerability of synaptic plasticity in the complexin II knockout mouse to maternal deprivation stress.
    Yamauchi Y, Qin LH, Nishihara M, Sawada K, Kato K, Inoue S.
    Brain Res; 2005 Sep 14; 1056(1):59-67. PubMed ID: 16112091
    [Abstract] [Full Text] [Related]

  • 17. Behavioral and electrophysiological effects of the adenosine A2A receptor antagonist SCH 58261 in R6/2 Huntington's disease mice.
    Domenici MR, Scattoni ML, Martire A, Lastoria G, Potenza RL, Borioni A, Venerosi A, Calamandrei G, Popoli P.
    Neurobiol Dis; 2007 Nov 14; 28(2):197-205. PubMed ID: 17720507
    [Abstract] [Full Text] [Related]

  • 18. Calcineurin inhibitors cause an acceleration of the neurological phenotype in a mouse transgenic for the human Huntington's disease mutation.
    Hernández-Espinosa D, Morton AJ.
    Brain Res Bull; 2006 May 31; 69(6):669-79. PubMed ID: 16716837
    [Abstract] [Full Text] [Related]

  • 19. Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice.
    Bolivar VJ, Manley K, Messer A.
    Brain Res; 2004 Apr 16; 1005(1-2):29-35. PubMed ID: 15044061
    [Abstract] [Full Text] [Related]

  • 20. Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice.
    Hebb AL, Robertson HA, Denovan-Wright EM.
    Eur Neuropsychopharmacol; 2008 May 16; 18(5):339-63. PubMed ID: 17913473
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.